Drug intelligence / Profile preview

PTH-0366

Development stage: Unknown
Lead developer: Protheragen
Modality: Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

PTH-0366 is a recombinant protein therapy designed to mimic the activity of human tissue kallikrein-1 (KLK1). Developed by Protheragen, the drug is intended for the treatment of acute ischemic stroke. KLK1 is a serine protease that cleaves low-molecular-weight kininogen to produce kinins, such as bradykinin, which interact with B1 and B2 receptors to induce vasodilation, inhibit inflammation, and provide neuroprotective effects. By restoring or enhancing KLK1 activity, PTH-0366 aims to improve cerebral blood flow and reduce tissue damage following an ischemic event. The program is currently in Phase I clinical development.

Other names: kallikrein-1kallikrein1kallikrein 1tissue kallikrein

Targets

KLK1 (Kallikrein-1)

Beyond the preview

Go deeper on PTH-0366.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTH-0366.

Explore the full profile